Potent antitumor activity of 3,4-seco-8βH-ferna-4(23),9(11)-dien-3-oic acid (EC-2) and 3,4-seco-oleana-4(23),18-dien-3-oic acid (EC-4), evaluated by an in vitro human cancer cell line panel

Planta Medica

Volumn 72, Issue 14, 2006, Pages 1347-1349

  Tanaka, Reiko ^a   Wada, Shun Ichi ^a   Yamada, Takeshi ^a   Yamori, Takao ^b  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 SECO 8BETAH FERNA 4(23),9(11) DIEN 3 OIC ACID; 3,4 SECO OLEANA 4(23),9(11) DIEN 3 OIC ACID; EC 2; EC 4; EUPHORBIA EXTRACT; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ISOLATION; DRUG MECHANISM; DRUG POTENCY; DRUG SENSITIVITY; EUPHORBIA; EUPHORBIA CHAMAESYCE; HUMAN; HUMAN CELL; IN VITRO STUDY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; EUPHORBIA; HUMANS; PHYTOTHERAPY; PLANT EXTRACTS;

CHAMAESYCE PROSTRATA;

EID: 33845265305     PISSN: 00320943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-951735     Document Type: Article

References (10)

1. Tanaka R, Ida T, Kita S, Kamisako W, Matsunaga S. 3,4-seco-Oleana- 8βH-fernadienoic acid and other constituents from Euphorbia chamaesyce. Phytochemistry 1996; 41: 1163-8
2. Tanaka R, Ida T, Takaoka Y, Kita S, Kamisako W, Matsunaga S. 3,4-seco-Oleana-4(23),18-dien-3-oic acid and other triterpenes from Euphorbia chamaesyce. Phytochemistry 1994; 36: 129-32
3. Wada S, Tanaka R, Iida A, Matsunaga S. In vitro inhibitory effects of DNA topoisomerase II by fernane-type triterpenoids isolated from a Euphorbia genes. Bioorg Med Chem Lett 1998; 28: 1219-23
4. Karim R, Iwai S, Morimura K, Wanibuchi H, Tanaka R, Matsunaga S et al. Lack of modification of rat hepatocarcinogenesis by fernane-type triterpenoids, isolated from a Euphorbia genus. Teratog Carcinog Mutagen 2002; 22: 293-9
5. Yamori T, Matsunaga A, Sato S, Yamazaki K, Komi A, Ishizu K et al. Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel. Cancer Res 1999; 59: 4042-9
6. Paull KD, Shomaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithum. J Natl Cancer Inst 1989; 81: 1088-92
7. Takada Y, Aggarwal BB. Betulinic acid suppresses carcinogen-induced NF-κB activation through inhibition of IκBa kinase and p65 phosphorylation: abrogation of cyclooxygenase-2 and matrix metalloprotease-9. J Immunol 2003; 171: 3278-86
8. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991; 83: 757-66
9. Stinson SF, Alley MC, Kopp WC, Fiebig HH, Mullendore LA, Pittman AF et al. Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen. Anticancer Res 1992; 12: 1035-53
10. Yaguchi S, Fukui Y, Koshimizu I, Yoshimi H, Matsuno T, Gouda H et al. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst 2006; 98: 545-56